Drug Trial Radar · NCT01061736
Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients
Last checked: Nov 20, 2026Latest source record: Jun 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,675
Actual
Start
Mar 2010
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Feb 3, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objectives: Part A (dose ranging study): To demonstrate that sarilumab (SAR153191/REGN88) on top of MTX was effective on reduction of signs and symptoms of rheumatoid arthritis at 12 weeks. Part B (pivotal study): To demonstrate that sarilumab added to MTX was effective in: * reduction of signs and symptoms of rheumatoid arthritis at 24 weeks * inhibition of progression of structural damage at 52 weeks * improvement in physical function at 16 weeks Secondary Objectives: Part B: To demonstrate that sarilumab added to MTX was effective in induction of a major clinical response at 52 weeks To assess the safety of sarilumab added to MTX To document the pharmacokinetic profile of sarilumab added to MTX in participants with active rheumatoid arthritis who were inadequate responders to MTX therapy.
Conditions
- Rheumatoid Arthritis
Interventions
SarilumabDrug
Pharmaceutical form: solution for injection Route of administration: subcutaneous
Placebo (for sarilumab)Drug
Pharmaceutical form: solution for injection Route of administration: subcutaneous
MethotrexateDrug
Same weekly dose as received prior to enrollment
Folic AcidDrug
According to local standard
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12Time frame: Baseline to Week 12
- Part B: Percentage of Participants Achieving ACR20 Response at Week 24Time frame: Baseline to Week 24
- Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16Time frame: Baseline, Week 16
- Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52Time frame: Baseline, Week 52
Locations
262 sites in 36 countries. Site status is shown where the registry gives one.
Investigational Site Number 840070
Anniston, Alabama
Investigational Site Number 840004
Birmingham, Alabama
Investigational Site Number 840072
Gilbert, Arizona
Investigational Site Number 840029
Beverly Hills, California
Investigational Site Number 840007
Palm Desert, California
Investigational Site Number 840008
San Francisco, California
Investigational Site Number 840021
Santa Maria, California
Investigational Site Number 840049
Upland, California
Investigational Site Number 840050
Dunedin, Florida
Investigational Site Number 840041
Jacksonville, Florida
Investigational Site Number 840067
Jupiter, Florida
Investigational Site Number 840048
Miami, Florida
Investigational Site Number 840006
Orlando, Florida
Investigational Site Number 840063
Palm Harbor, Florida
Investigational Site Number 840060
Sarasota, Florida
Investigational Site Number 840003
Atlanta, Georgia
Investigational Site Number 840028
Decatur, Georgia
Investigational Site Number 840027
Marietta, Georgia
Investigational Site Number 840018
Idaho Falls, Idaho
Investigational Site Number 840046
Chicago, Illinois
Investigational Site Number 840015
Lexington, Kentucky
Investigational Site Number 840073
Cumberland, Maryland
Investigational Site Number 840055
Frederick, Maryland
Investigational Site Number 840013
Wheaton, Maryland
Investigational Site Number 840066
St Louis, Missouri
Investigational Site Number 840071
Omaha, Nebraska
Investigational Site Number 840056
New York, New York
Investigational Site Number 840068
Hickory, North Carolina
Investigational Site Number 840044
Toledo, Ohio
Investigational Site Number 840002
Oklahoma City, Oklahoma
Investigational Site Number 840011
Tulsa, Oklahoma
Investigational Site Number 840065
Tulsa, Oklahoma
Investigational Site Number 840010
Bethlehem, Pennsylvania
Investigational Site Number 840009
Duncansville, Pennsylvania
Investigational Site Number 840062
Reading, Pennsylvania
Investigational Site Number 840058
Columbia, South Carolina
Investigational Site Number 840016
North Charleston, South Carolina
Investigational Site Number 840025
Jackson, Tennessee
Investigational Site Number 840001
Dallas, Texas
Investigational Site Number 840022
Dallas, Texas
Showing 40 of 262 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.